Peptide Comparison
Hexarelin vs Sermorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Hexarelin and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Phase 2 (not approved) / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Hexarelin | Sermorelin | |
|---|---|---|
| Class | GHRP; potent ghrelin receptor agonist | GHRH analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; more potent GH release than other GHRPs | Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release |
| Route | SC / Intranasal | SC injection |
| Half-life | ~1 hr | ~10-20 min |
| Dosage (research) | 100-200 mcg SC 1-2x daily (short cycles) | 200-500 mcg SC at bedtime daily |
| Evidence tier | Phase 2 (not approved) | Discontinued (FDA approval 1990; US withdrawal 2008) |
| Research depth | 158 indexed | 149 indexed |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Cortisol/prolactin elevation; pituitary desensitization | Injection site reactions; headache; flushing |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Hexarelin or Sermorelin?
Hexarelin and Sermorelin share the gh-secretagogue class and carry roughly equivalent evidence (Phase 2 (not approved) / Discontinued (FDA approval 1990; US withdrawal 2008)). On the catalogued data layer Sermorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Sermorelin's evidence base is currently denser.
What is the difference between Hexarelin and Sermorelin?
Hexarelin is classed as GHRP; potent ghrelin receptor agonist; Sermorelin is classed as GHRH analog. Reported mechanism: Hexarelin, GHS-R1a agonist; more potent GH release than other GHRPs; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: Hexarelin, ~1 hr; Sermorelin, ~10-20 min. Routes in published studies: Hexarelin, SC / Intranasal; Sermorelin, SC injection.
Which has stronger evidence, Hexarelin or Sermorelin?
Hexarelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Hexarelin is graded Phase 2 (not approved), with 4 cited sources on its reference page and 158 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies.
Which is more accessible, Hexarelin or Sermorelin?
Neither Hexarelin nor Sermorelin is an FDA-approved drug. Catalog status: Hexarelin, Research Chemical; Sermorelin, Compounding Restricted.
Are Hexarelin and Sermorelin ever combined?
Hexarelin and Sermorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…